‘Response rate to top selling drugs is 10%’, says Scipher CEO

white, yellow, and blue pills

Scipher’s CEO Alif Saleh discusses trial results and what it means for precision medicine

Alif explains to inPharma Technologist the problem of low drug response rates to the world’s largest selling drugs and the positive outcomes of PrismRA’s retrospective trial with In-Pharma Technologist.

This test could double response rate to these major therapies, bringing both clinical and financial benefits to patients and the healthcare industry.